2024
Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis
Daniele S, Eldirany S, Damiani G, Ho M, Bunick C. Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. JID Innovations 2024, 4: 100261. PMID: 38445231, PMCID: PMC10914523, DOI: 10.1016/j.xjidi.2024.100261.Peer-Reviewed Original ResearchIL-23Clinical efficacyIL-23 inhibitors risankizumabSurface areaLong-term clinical efficacyMolecular propertiesIL-23 inhibitorsSolvent accessible surface areaHydrogen-deuterium exchangeIL-23 p19 subunitAccessible surface areaAssociated with short-Clinical efficacy scorePlaque psoriasisClinical responseP19 subunitCrystallographic experimentsPsoriasis pathogenesisReceptor epitopesInhibitor epitopesPsoriasisLinear regression analysisEfficacyTherapeutic classesBinding affinity
2023
1097 The structure of IL-23 inhibitor epitopes correlates with short-term clinical efficacy in plaque psoriasis
Daniele S, Eldirany S, Bunick C. 1097 The structure of IL-23 inhibitor epitopes correlates with short-term clinical efficacy in plaque psoriasis. Journal Of Investigative Dermatology 2023, 143: s188. DOI: 10.1016/j.jid.2023.03.1109.Peer-Reviewed Original Research